About
Clene Nanomedicine, Inc. is a clinical-stage biopharmaceutical company based in Salt Lake City, Utah, founded in 2013. The company focuses on developing nanotherapeutics, particularly nanocatalysts, aimed at treating neurodegenerative diseases by addressing cellular energy impairments and enhancing neuronal health. Clene's lead product, CNM-Au8, is currently in a Phase 3 clinical study for amyotrophic lateral sclerosis (ALS) and is also being developed for multiple sclerosis and Parkinson's disease. The company has a robust pipeline that includes small molecule drugs, with several candidates in advanced clinical phases. Clene is dedicated to pioneering innovative treatments that target the underlying mechanisms of neurodegenerative conditions, moving beyond mere symptom management.